We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2.32B
1-Year Est. Return
536.01%
This Fund
S&P 500
This Quarter
Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
(+16%)
Cap. Flow
-$21M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$95.5M |
| 2 |
Vera Therapeutics
VERA
|
+$82M |
| 3 |
Celldex Therapeutics
CLDX
|
+$53.3M |
| 4 |
ABVX
Abivax
ABVX
|
+$39.5M |
| 5 |
BLTE
Belite Bio
BLTE
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$190M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$84.4M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$79.1M |
| 4 |
Cytokinetics
CYTK
|
+$57.7M |
| 5 |
United Therapeutics
UTHR
|
+$47.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Enliven Therapeutics
ELVN
$4.24B
| – | – |
-500,000
| Closed | -$19.6M |
|
77
iBio
IBIO
$67.6M
| – | – |
-1,300,000
| Closed | -$2.47M |
|
78
Janux Therapeutics
JANX
$1.1B
| – | – |
-1,000,000
| Closed | -$13.9M |
|
79
Madrigal Pharmaceuticals
MDGL
$12.3B
| – | – |
-85,000
| Closed | -$44.5M |
|
80
MeiraGTx Holdings
MGTX
$1.33B
| – | – |
-700,000
| Closed | -$6.06M |
|
81
Mirum Pharmaceuticals
MIRM
$5.94B
| – | – |
-200,000
| Closed | -$18.5M |
|
82
NewAmsterdam Pharma
NAMS
$3.1B
| – | – |
-600,000
| Closed | -$19.2M |
|
83
Oric Pharmaceuticals
ORIC
$1.37B
| – | – |
-950,000
| Closed | -$12M |
|
84
Vaxcyte
PCVX
$8.9B
| – | – |
-300,000
| Closed | -$17.4M |
|
85
Pharvaris
PHVS
$2.48B
| – | – |
-65,000
| Closed | -$1.84M |
|
|
SLNO
86
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-250,000
| Closed | -$8.37M |
|
|
TERN
87
CALL
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-500,000
| Closed | -$26.4M |
|
|
TERN
88
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-1,500,000
| Closed | -$79.1M |
|
89
Tyra Biosciences
TYRA
$1.49B
| – | – |
-850,000
| Closed | -$32.6M |
|
|
90
United Therapeutics
UTHR
$22.1B
| – | – |
-80,000
| Closed | -$47.4M |
|
91
Verastem
VSTM
$654M
| – | – |
-1,000,000
| Closed | -$5.3M |
|
Similar funds
MAP
CWM
PA
NP
AI
GGH
HHGA
TWA
Logos Global Management's Q2 2026 Portfolio in Review
As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.
- Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
- Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
- Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
- Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
- Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
- Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
- Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.
Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.